Extended Data Fig. 5: Replication and monitoring of CpG reversion during passage of CpG enriched EV-A71.
From: Rational attenuation of RNA viruses with zinc finger antiviral protein
(a) EV-A71 RNA levels measured at the end of passage #5, 60 h post-infection in three replicate cultures (mean and s.d. of 3 replicates is plotted). (b) PCR amplification of the modified region of EV-A71/CG-48/A+ in three replicates at the end of a long-term passage in ZAP+/+ and ZAP−/− cells (amplified region is approximately 1 kb). (c–e) Replication of EV-A71 wildtype and mutant reporter viruses in ZAP+/+ and ZAP−/− HeLa cells. NanoLuc luciferase activity was measured every 12 h (c), or quantification of viral RNA at day 4 (d), mean and s.d. plotted; data from 3 replicates. Alternatively replication of EV-A71 wildtype and mutant viruses monitored by TCID50 measurement at each timepoint (e); 3 replicates shown.
